SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

According to the company, the analysis evaluated patients enrolled in the SYMPHONY-PE investigational device exemption study, which supported FDA clearance of Imperative Care’s Symphony thrombectomy system for PE in August 2025. This system has been used to treat more than 500 patients with PE since its launch in the United States.

Sripal Bangalore, MD, et al published the study findings in Circulation: Cardiovascular Interventions.

Imperative Care stated that the study investigators examined outcomes according to the interval between diagnostic CT pulmonary angiography and thrombectomy, defining early treatment as < 12 hours and late treatment as ≥ 12 hours, noted Imperative Care. The analysis included 109 patients, of whom 48 (44%) underwent early thrombectomy.

As summarized in the company’s press release, the study found that mean pulmonary artery pressure decreased more in the early treatment group than in the late treatment group (8.6 vs 5.8; P = .006). Patients treated within 12 hours also experienced a greater reduction in right ventricular/left ventricular (RV/LV) ratio at 48 hours compared with those treated later (0.52 vs 0.37; P = .071).

The greatest differences in efficacy outcomes were observed among patients classified as higher risk per the Composite Pulmonary Embolism Shock score, noted the company.

The investigators further reported that repeat traversal of the right heart with the Symphony system was required in 4.6% of cases (5/109), including two procedures in the early-treatment group and three in the late-treatment group.

Finally, safety outcomes were similar between groups. One major adverse event occurred within 48 hours in the early-treatment group, while no major adverse events occurred in the late-treatment group. No device-related serious adverse events and no deaths were reported in either cohort.

“While thrombectomy can be beneficial for patients with intermediate-risk PE regardless of when it is performed after diagnosis, data from the SYMPHONY-PE trial add to the growing body of observational evidence suggesting that earlier catheter-based intervention may accelerate cardiac recovery, as reflected by greater reductions in RV/LV ratio and mean pulmonary artery pressure,” commented Dr. Bangalore in the company’s press release. “Randomized controlled trials are desirable to determine optimal treatment timing and to identify whether patients with certain risk factors are more likely to benefit from early intervention than others.”